Abstract-Effects of a novel dihydropyridine type of antihypertensive drug, cilnidipine, on the regulation of the catecholamine secretion closely linked to the intracellular Ca 2ϩ were examined using nerve growth factor (NGF)-differentiated rat pheochromocytoma PC12 cells. By measuring catecholamine secretion with high-performance liquid chromatography coupled with an electrochemical detector, we showed that high K ϩ stimulation evoked dopamine release from PC12 cells both before and after NGF treatments. Cilnidipine depressed dopamine release both from NGF-treated and untreated PC12 cells in a concentration-dependent manner. In contrast, inhibition by nifedipine was markedly decreased in the differentiated PC12 cells. With intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) measurements using fura 2, the elevation of high K ϩ -evoked [Ca 2ϩ ] i was separated into nifedipine-sensitive and -resistant components. The nifedipine-resistant [Ca 2ϩ ] i increase was also blocked by cilnidipine, as well as -conotoxin-GVIA. By the use of the conventional whole-cell patch-clamp technique, the compositions of the high-voltage-activated Ca 2ϩ channel currents in the NGF-treated PC12 cells were divided into types: L-type, N-type, and residual current components. It was also estimated that cilnidipine at 1 and 3 mol/L strongly blocked the N-type current without affecting the residual current. These results suggest that cilnidipine inhibits catecholamine secretion from differentiated PC12 cells by blocking Ca 2ϩ influx through the N-type Ca 2ϩ channel, in addition to its well-known action on the L-type Ca 2ϩ channel. (Hypertension. 1998;31:1195-1199.)
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Key Words: cilnidipine Ⅲ calcium channels Ⅲ calcium, cytoplasmic Ⅲ dopamine C ilnidipine (FRC-8653) is a newly synthesized DHP type of organic Ca 2ϩ channel blocker that has been developed as a slow-onset and long-lasting antihypertensive drug in Japan. 1, 2 Recent electrophysiological data indicate that cilnidipine might be a dual-channel antagonist for peripheral neuronal N-type and vascular L-type Ca 2ϩ channels. [3] [4] [5] In humans and rodents, cilnidipine depressed the pressor response to acute cold stress but failed to induce tachycardia evoked by hypotensive baroreflexes. 6, 7 In spontaneously hypertensive rats, vasoconstriction induced by electrical sympathetic nerve stimulation was also blocked by cilnidipine. 8 In in vitro experiments, cilnidipine also inhibited [ 3 H]norepinephrine release evoked by electrical stimulation in the rabbit mesenteric artery. 9 PC12 cells are derived from a rat pheochromocytoma cell line that is very popular for investigating neuronal differentiation. In response to externally applied NGF, PC12 cells acquire sympathetic neuronal characteristics such as neurite extension, increased CA synthesis, and expression of neuronal types of voltage-dependent N-type Ca 2ϩ channels. 10 -12 Therefore, the differentiated PC12 cells are widely used as model cells for studying the intracellular mechanisms of the stimulus-secretion coupling, including the activation of the N-type Ca 2ϩ channel. 13, 14 With this model cell, it has been revealed that endogenous substances such as neuropeptide Y and proadrenomedullin N-terminal 20 peptide inhibit CA release by inhibiting Ca 2ϩ influx through N-type Ca 2ϩ channels. 15, 16 In the present study, we examined the effects of cilnidipine on the cellular functions of the NGF-treated PC12 cells, including CA secretion and intracellular Ca 2ϩ mobilization triggered by membrane depolarizations. Consequently, in addition to its well-known L-type Ca 2ϩ channel blockade, 3 it was clarified that cilnidipine had a potent inhibitory effect for CA secretion from differentiated PC12 cells via the blockade of extracellular Ca 2ϩ influx through the N-type Ca 2ϩ channel.
Methods

Cell Culture
PC12 cells were prepared as described previously. 17 In brief, cells were cultured in Dulbecco's modified Eagle's medium containing 7% fetal bovine serum (Gibco), 7% heat-inactivated (56°C, 40 minutes) horse serum (Cell Culture Laboratories), 2 mmol/L L-glutamine, and 50 g/mL gentamicin sulfate (Boehringer Mannheim GmbH) in a humidified atmosphere of 90% air and 10% CO 2 at 37°C. Cells were plated onto poly-L-lysine-coated glass coverslips (24ϫ60ϫ0.15 mm), placed in silicone rubber walls (Flexiperm, W.C. GmbH) at a density of 2. 
Dopamine Release
The released DA was measured as described by Ohara-Imaizumi et al. 18 All the procedures, including incubation, washing, and drug application, were performed at room temperature using 1 mL per dish of balanced salt solution (BSS) with the following composition (mmol/L): NaCl 150, KCl 5, CaCl 2 1.2, MgCl 2 1.2, D-glucose 10, and HEPES 25 (pH adjusted to 7.4 with NaOH). Cells were incubated with BSS for 1 hour, and then the BSS containing 80 mmol/L KCl was added to the dishes and incubated for 1 minute. At the end of the incubation period, solutions were transferred to tubes containing 0.25 mL of 1 mol/L HClO 4 . Cells were then sonicated, and DA residing in cells was extracted with 0.2 mol/L HClO 4 . After centrifugation (at 4°C for 5 minutes, 10 000g), supernatants of both incubation solutions and the sonicated cellular solutions were collected for the measurement of DA content. DA content was determined with high-performance liquid chromatography coupled with an electrochemical detector (HPLC/ECD). Each supernatant (20 L) was applied to the HPLC/ECD system, which consisted of a reversephase HPLC column (ODS, 0.003 mm; 4.6ϫ150 mm) and an ECD (LC-4B and TL-5A, Bioanalytical Systems) with the electrode potential set at ϩ0.6 V versus the Ag/AgCl reference electrode. The mobile phase consisted of a monochloroacetate buffer (140 mmol/L, pH 3.05) containing 10% methanol, 30 mg/L sodium 1-octanesulfonate, and 1.8 mmol/L EDTA. Flow rate was 1.3 mL/min. The data were analyzed with a chromatographic processor (Shimazu C-R4A, Shimazu Corp). The percentage of DA release was calculated using the values obtained for the DA content in the incubation solution (A) and the DA content remaining in the cells (B) using the following equation: % of total DA contentsϭ100ϫA/(AϩB).
[Ca 2؉ ] i Measurements
The increase in [Ca 2ϩ ] i in single cells was measured by the fura 2 method as described by Grynkiewicz et al 19 with minor modifications. The cells were washed with BSS and incubated with 10 mol/L fura 2-AM (Dojindo) at 37°C in BSS. Thirty minutes later, the cells were washed twice with 0.2 mL BSS. The coverslips were mounted on an Olympus IMT-2 inverted epifluorescence microscope equipped with a 75-W xenon lamp and band-pass filters of 340-nm wavelength for detection of Ca -independent signal (F 360 ). Measurements were carried out at room temperature. Image data, recorded by a high-sensitivity silicon intensifier target camera (C-2741-08, Hamamatsu Photonics), were processed by a personal computer.
Electrophysiological Measurements
Electrical measurements were performed in a whole-cell mode by using a conventional patch-clamp technique. 20, 21 The resistance between the recording electrode filled with internal solution and reference electrode in external solution was 2 to 5 M⍀. The current and voltage were measured with a patch-clamp amplifier (List Medical, EPC-7), monitored on a storage oscilloscope (Iwatsu DS-9121), and then stored on DAT tape with a PCM processor (TEAC RD-120TE) after being filtered at 1 kHz (NF Instruments). Then, analog signals were reconverted into digital signals with an AD converter at a sampling frequency of 3 kHz; the signals were stored with an IBM-compatible computer using pClamp software (Axon Instruments). The capacitative and leak currents were subtracted by hyperpolarizing pulses. All experiments were performed at room temperature (20°C to 22°C). The ionic composition of Ba 
Drugs
-Cg-GVIA was purchased from the Peptide Institute (Osaka, Japan). Fura 2-AM and HEPES were from Dojindo. NGF (7S) was from Gibco BRL. Nifedipine and all other chemicals were obtained from Sigma Chemical Co. Cilnidipine [2-methoxyethyl(E)-3-phenyl-2-propen-1-yl(Ϯ)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl) pyridine-3,5-dicarboxylate] was synthesized at the Ajinomoto central research laboratories (Kawasaki, Japan). All drugs were dissolved in external solution just before use.
Data Analysis
Experimental values are presented as meanϮSEM. Statistical differences in values for DA release or [Ca 2ϩ ] i increase were determined using ANOVA followed by Dunnett's test for multiple comparison; a value of PϽ.05 was considered to be significant.
Results
Effects of Cilnidipine on CA Secretion From Differentiated PC12 Cells
Rat PC12 cells exhibited neurite outgrowth in response to externally applied NGF (100 ng/mL) for 8 days (Fig 1) . Rat PC12 cells used in the present study were changed to contain norepinephrine in addition to DA. However, since the amount of norepinephrine content was less than that of DA (data not shown), we measured the rate of DA production as an indication of the CA release process in the following experiments. Depolarization with 80 mmol/L KCl evoked DA release from the PC12 cells both before and after the NGF treatments (8.53Ϯ0.65% release of a total DA content in undifferentiated PC12 cells and 7.21Ϯ0.49% in the differentiated PC12 cells; each nϭ12). This stimulation was dependent on extracellular Ca 2ϩ influx through voltage-dependent Ca 2ϩ channels because it was completely prevented by addition of 100 mol/L Cd 2ϩ , a nonselective inorganic Ca 2ϩ channel antagonist (nϭ3). The DHP types of Ca 2ϩ channel
Selected Abbreviations and Acronyms
CA ϭ catecholamine -Cg-GVIA ϭ -conotoxin GVIA DA ϭ dopamine DHP ϭ dihydropyridine HVA I Ba ϭ high-voltage-activated Ba 2ϩ current NGF ϭ nerve growth factor Figure 1 . Phase-contrast micrographs of the undifferentiated (A) and differentiated (B) rat PC12 cells used in the present study. Each culture condition is described in the text. After 8 days of 100 ng/mL NGF treatment, rat PC12 cells were well differentiated enough to exhibit neurite outgrowth. Scale bar, 60 m.
antagonists, cilnidipine and nifedipine, strongly blocked DA release from the undifferentiated PC12 cells (Fig 2) . The IC 50 values for cilnidipine and nifedipine were Ϸ6ϫ10 Ϫ7 and 8ϫ10 Ϫ8 mol/L, respectively. In contrast, in the NGF-differentiated PC12 cells, inhibitory potency of nifedipine was markedly reduced (Fig 2B) , whereas the inhibitory effect of cilnidipine was almost equal (Fig 2A) to that observed in the PC12 cells. The IC 50 values for cilnidipine and nifedipine were 7ϫ10
Ϫ8 and Ͼ10 Ϫ5 mol/L, respectively. NGF differentiation also reduced the blocking potency of L-type Ca 2ϩ channel antagonists other than nifedipine, such as verapamil (phenylalkylamine-type) and diltiazem (benzothiazepinetype). The inhibitory percentages of 10 mol/L verapamil and 10 mol/L diltiazem on 80 mmol/L KCl-evoked DA release were 82.48Ϯ2.06% and 72.27Ϯ5.53% (each, nϭ3) in the undifferentiated PC12 cells and 37.99Ϯ2.29% and 41.02Ϯ1.40% (each, nϭ3) in the NGF-differentiated PC12 cells, respectively. In contrast, an N-type Ca 2ϩ channel antagonist peptide, -Cg-GVIA, had no effect on the high K ϩ -evoked DA release from undifferentiated cells (0.84Ϯ6.29% inhibition, nϭ6) but inhibited the DA release from the differentiated PC12 cells (39Ϯ5.1% inhibition, nϭ6). This observation strongly indicated that the DA release mediated by the N-type Ca 2ϩ channel activation was caused by the cell differentiation.
As a next step, we estimated whether the potent blocking action of cilnidipine on the DA release from the differentiated cells might be derived from the blockade of channels other than the L-type Ca 2ϩ channel. We examined the effect of cilnidipine on the residual releases after abolishing the L-type Ca 2ϩ channel-dependent DA release by nifedipine. About 58% of the high K ϩ -evoked DA releases from the NGF-differentiated cells remained, even in the presence of 10 mol/L nifedipine (nϭ6). Under these conditions, it was clarified that cilnidipine (1 mol/L) as well as -Cg-GVIA (1 mol/L) inhibited the nifedipine-resistant DA release (Fig 3) . (Fig 4A,a) or cilnidipine in a concentration-dependent manner (Fig 4A,b) . Under this experimental condition, we confirmed that the initial high K ϩ response was reproducible at least for four stimulations (data not shown, nϭ3). The quantitative results are summarized in Fig 4B. The nifedipine-resistant [Ca 2ϩ ] i elevation was significantly blocked by cilnidipine as well as -Cg-GVIA. In addition, the nifedipine-and -Cg-GVIA-resistant [Ca 2ϩ ] i elevation was not influenced by the further application of 10 mol/L cilnidipine (72Ϯ9% inhibition, nifedipine plus -Cg-GVIA; 68Ϯ11% inhibition, nifedipine plus -Cg-GVIA plus cilnidipine, each nϭ10). These results suggest that cilnidipine blocks Ca 2ϩ influx through nifedipine-resistant Ca 2ϩ channels (possibly N-type).
Effects of Cilnidipine on [
Cilnidipine Blockade of HVA Ca 2؉ Current in Differentiated Rat PC12 Cells
Finally, the direct effect of cilnidipine on the Ca 2ϩ channels in the differentiated rat PC12 cells was investigated by using the channels. The typical current traces are shown in Fig 5A, a. In this experiment, 1 mol/L -Cg-GVIA was first applied to the cell, then 10 mol/L nifedipine was applied, and finally 100 mol/L Cd 2ϩ was applied. The composition of the HVA I Ba was classified into current compounds that were -Cg-GVIA-sensitive (N-type: 40Ϯ12% of total HVA I Ba , nϭ6), nifedipine-sensitive (L-type: 13Ϯ2% of total HVA I Ba , nϭ6), and insensitive to those two compounds (possibly R-type: 37Ϯ7% of total HVA I Ba , nϭ6). Cilnidipine blocked the HVA I Ba after the L-type component was abolished by 10 mol/L nifedipine (Fig 5A,b and 5B). Blocking potencies of 3 and 10 mol/L cilnidipine for the -Cg-GVIA-sensitive I Ba component were 53Ϯ8% and 75Ϯ10%, respectively (nϭ4). Finally, the effect of cilnidipine on the residual non-L-type and N-type component was also examined (Fig 6) . In this experiment, L-and N-type components were completely abolished by treatment with 10 mol/L nifedipine and 1 mol/L -Cg-GVIA (Fig 6A) . Consequently, cilnidipine failed to inhibit the -Cg-GVIA-and nifedipine-resistant current up to 3 mol/L. These results suggest that cilnidipine blocks -Cg-GVIA-sensitive N-type current component in differentiated rat PC12 cells.
Discussion
In the present experiment, we investigated the effects of cilnidipine on DA release, [Ca 2ϩ ] i elevation, and Ca 2ϩ channel currents in differentiated rat PC12 cells. The PC12 cells used in this study clearly showed neurite outgrowth, and Ϸ50% of HVA Ca 2ϩ channel currents were composed of -Cg-GVIAsensitive N-type Ca 2ϩ currents. A typical L-type Ca 2ϩ channel blocker such as nifedipine had a small effect on the Ca In the present study, we clearly showed that a DHP type of antihypertensive drug, cilnidipine, strongly inhibited the high K ϩ -evoked CA secretion, [Ca 2ϩ ] i elevation, and HVA Ca 2ϩ channel currents in differentiated rat PC12 cells. In contrast to cilnidipine, the selective L-type Ca 2ϩ channel antagonist nifedipine showed a weak inhibition on all three parameters in the PC12 cells after differentiation by NGF (Fig 1B) . Cilnidipine directly blocked the isolated N-type channel current (IC 50 value, Ϸ1 mol/L) but had no effect on the R-type channel current in the differentiated rat PC12 cells (Figs 5 and 6 ). This observation agreed with previous findings using rat superior ganglion neurons 5 and dorsal horn ganglion neurons. 4 Blockade of N-type Ca 2ϩ channels by cilnidipine results in reduced Ca 2ϩ influx through these channels and thereby reduces CA secretions closely linked with [Ca 2ϩ ] i elevation, which is evoked by various depolarizing stimulations. It is well characterized that Ca 2ϩ influx through N-type Ca 2ϩ channels is closely related to the CA secretion at the nerve endings of the sympathetic neurons as well. 23 The blockade of CA secretion from the differentiated PC12 cells might well explain why cilnidipine failed to induce elevation of plasma CA concentration by hypotensionevoked baroreflexes in vivo 7 or why the drug blocked the norepinephrine release from isolated vessels. 9 Sources of plasma CA were mainly sympathetic nerve endings and adrenal chromaffin cells, at which N-type Ca 2ϩ channels were predominantly distributed. It was reported that the blockade of peripherally distributed N-type Ca 2ϩ channels by -Cg-GVIA led to reduction of plasma CA concentration by inhibition of its secretion from the vascular beds 24 and adrenal glands. 25 Especially, it is well known that CA secretion from sympathetic neurons is insensitive to L-type Ca 2ϩ channel antagonist but sensitive to -Cg-GVIA. 23 Therefore, cilnidipine with N-type Ca 2ϩ channel blocking action may offer a new choice in treating hypertension which is refractory to hypotensive Ca 2ϩ channel antagonists or results from increased sympathetic nerve activity. In keeping with these therapeutic implications, recent observations in rats and humans revealed that the oral administration of cilnidipine successfully reduced blood pressure elevated by stress stimulations. 6, 8 It might also be clinically used for controlling malignant hypertension resulting in hypersecretion of CA from human pheochromocytoma, because the PC12 cells used here are derived from rat pheochromocytoma cells.
